HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

An analysis of sestamibi-positive versus -negative patients with primary hyperparathyroidism.

Abstract
We performed this study to evaluate two patient groups with primary hyperparathyroidism depending on whether their abnormal gland(s) could be preoperatively imaged with sestamibi. Patients with primary hyperparathyroidism evaluated by preoperative sestamibi examination from January 1999 to June 2000 were divided into two groups depending on the ability of sestamibi to localize their disease. Records were reviewed to determine pre- and postoperative biochemical data, weight of the excised glands, and total operating room time. When the sestamibi imaging was positive a minimally invasive parathyroidectomy was performed; however, when sestamibi scanning was negative patients underwent a formal bilateral neck exploration. All 40 patients in the sestamibi-positive group and 17 of 18 patients in the sestamibi-negative group were cured of their primary hyperparathyroidism as a result of surgery. Sestamibi scanning with a minimally invasive parathyroidectomy shortens operating room time and is most effective when adenomas are large. The results of this study suggest that strategies to preoperatively increase the activity of adenomas may improve the sensitivity of sestamibi scan localization of parathyroid adenomas.
AuthorsR J Parel, J S Bolton, G M Fuhrman
JournalThe American surgeon (Am Surg) Vol. 67 Issue 11 Pg. 1101-4 (Nov 2001) ISSN: 0003-1348 [Print] United States
PMID11730230 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • Radiopharmaceuticals
  • Technetium Tc 99m Sestamibi
Topics
  • Adenoma (complications, radionuclide imaging)
  • Female
  • Humans
  • Hyperparathyroidism (etiology)
  • Male
  • Middle Aged
  • Minimally Invasive Surgical Procedures
  • Parathyroid Neoplasms (complications, radionuclide imaging)
  • Parathyroidectomy (methods)
  • Predictive Value of Tests
  • Radiopharmaceuticals
  • Technetium Tc 99m Sestamibi

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: